NASDAQ$MMED

MiniMed Group, Inc · Q4 2026 earnings

Q4 2026 earnings · · Before market open

Briefing

MiniMed reported Q4 net sales of $837 million, up 15.6% year-over-year, and full-year sales exceeding $3 billion for the first time.

MiniMed delivered strong fourth-quarter results with worldwide net sales of $837 million, driven by international growth and new sensor launches. The company achieved record annual net sales of $3.102 billion and advanced its product pipeline with multiple regulatory clearances and launches. Fiscal 2027 outlook includes approximately 10% organic revenue growth and 16% adjusted EBITDA margin.

  • Q4 worldwide net sales reached $837 million, growing 15.6% as reported and 8.7% organic.
  • Full-year net sales hit a record $3.102 billion, up 14.2% as reported and 8.0% organic.
  • Worldwide new pumps sold totaled ~42,000 in Q4 with CGM attachment rate at 68%.
  • FY2027 guidance calls for ~10% organic revenue growth and ~16% adjusted EBITDA margin.

Headline financials

Total Revenue

$837M

No prior period
EPS (adj)

-$0.68

No prior period
Worldwide NPS

42.0K

No prior period
Global CGM Attachment Rate

68.0%

No prior period
Net Income

-$183M

No prior period
Operating Income

-$91M

No prior period
Gross Profit

$480M

No prior period

Revenue & EPS history

MiniMed Group, Inc · Revenue · Quarterly

$837M

Q4 2026
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Revenue by segment

MiniMed Group, Inc · $837M total across 4 segments · Q4 2026

  • CGM
    $420M
  • Consumables
    $249M
  • Pumps
    $146M
  • Other
    $22M

Forward guidance

For fiscal 2027, MiniMed expects organic revenue growth of approximately 10% and adjusted EBITDA margin of approximately 16%.

Tailwinds

  • Extra week in FY27 expected to add 1.0-1.5% to growth
  • New product launches including MiniMed Flex and MiniMed Go

Historical earnings impact

How earnings announcements have historically affected this stock's price.

+8.8%

Avg return

Earnings day

+7.1%

Avg return

5 days after

-23.0%

Avg return

30 days after

100%

2 / 2 earnings

Positive

+14.5%

Q4 2026

Best reaction

+3.0%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+14.5%+20.2%
Q3 2025+3.0%-5.9%-23.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro